Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Leptin Receptor (OB Receptor or CD295 or LEPR) Therapeutics Report 2016 - Pipeline Review of 5 Companies & 11 Drug Profiles - Research and Markets

Research and Markets
Posted on: 31 Aug 16

Research and Markets has announced the addition of the "Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016" report to their offering.

Leptin Receptor (OB Receptor or CD295 or LEPR) pipeline target constitutes close to 11 molecules, out of which approximately 11 molecules are developed by Companies.

Furthermore, the author says; Leptin Receptor (OB Receptor or CD295 or LEPR) Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The report 'Leptin Receptor - Pipeline Review, H1 2016' outlays comprehensive information on the Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics that are being developed by Companies/Universities, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 8 and 2 respectively.

Key Topics Covered:

  1. Introduction
  2. Leptin Receptor Overview
  3. Therapeutics Development
  4. Pipeline Products for Leptin Receptor - Overview
  5. Pipeline Products for Leptin Receptor - Comparative Analysis
  6. Leptin Receptor - Therapeutics under Development by Companies
  7. Leptin Receptor - Therapeutics under Investigation by Universities/Institutes
  8. Leptin Receptor Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Leptin Receptor - Products under Development by Companies
  13. Leptin Receptor - Products under Investigation by Universities/Institutes
  14. Leptin Receptor - Companies Involved in Therapeutics Development
  • Aegerion Pharmaceuticals, Inc.
  • Ambrx, Inc.
  • Jyant Technologies, Inc.
  • Neurotez, Inc.
  • XL-protein GmbH

For more information about this report visit http://www.researchandmarkets.com/research/vzrmtf/leptin_receptor

Related Topics: Anti-Obesity Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005632/en/

Business Wire
www.businesswire.com

Last updated on: 31/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.